Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in ReceivablesChange in Working CapitalDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Cash from Financing Activities (2022 - 2025)

Historic Cash from Financing Activities for Addex Therapeutics (ADXN) over the last 4 years, with Q2 2025 value amounting to -$118.4 billion.

  • Addex Therapeutics' Cash from Financing Activities rose 3495.05% to -$118.4 billion in Q2 2025 from the same period last year, while for Jun 2025 it was -$8.0 billion, marking a year-over-year increase of 9987.08%. This contributed to the annual value of $119260.5 for FY2024, which is 9796.55% down from last year.
  • Addex Therapeutics' Cash from Financing Activities amounted to -$118.4 billion in Q2 2025, which was up 3495.05% from $109.0 billion recorded in Q1 2025.
  • In the past 5 years, Addex Therapeutics' Cash from Financing Activities registered a high of $6130.2 billion during Q2 2023, and its lowest value of -$6000.8 billion during Q4 2023.
  • For the 4-year period, Addex Therapeutics' Cash from Financing Activities averaged around -$6.1 billion, with its median value being -$176047.7 (2022).
  • Over the last 5 years, Addex Therapeutics' Cash from Financing Activities had its largest YoY gain of 346783316935.01% in 2023, and its largest YoY loss of 342275858073.99% in 2023.
  • Over the past 4 years, Addex Therapeutics' Cash from Financing Activities (Quarter) stood at -$175321.9 in 2022, then tumbled by 3422758580.74% to -$6000.8 billion in 2023, then skyrocketed by 97.97% to -$121.7 billion in 2024, then rose by 2.77% to -$118.4 billion in 2025.
  • Its last three reported values are -$118.4 billion in Q2 2025, $109.0 billion for Q1 2025, and -$121.7 billion during Q4 2024.